Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Protein Degradation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IKZF3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | IKZF3 (Aiolos) Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. Ideal for SPR and ternary complex assays. |
View IKZF3 Products |
| Antigen (Resistance Mutant) | IKZF3 Q146H Mutant Protein Validated resistance variant for lenalidomide/pomalidomide escape mechanisms. >95% purity. |
View IKZF3 Products |
| Gene Delivery | IKZF3 Promise-ORF Lentivirus Full-length ORF for stable cell line construction. CMV promoter, Puro resistance. For monitoring proteasomal degradation. |
View IKZF3 Products |
| Benchmark Ab | Anti-IKZF3 Control Antibody Recombinant positive control for western blot and target engagement tracking. |
View IKZF3 Products |
| Validator | IKZF3 siRNA Set (3 pre-designed) For knockdown verification and specificity controls. >75% knockdown efficiency. |
View IKZF3 Products |
| Related Target: CRBN | Cereblon (CRBN) Recombinant Protein E3 ligase substrate receptor. Essential for ternary complex assays. |
View CRBN Products |
| Related Target: IKZF1 | Ikaros (IKZF1) Protein & Lentivirus Family member co-degraded by IMiDs. Essential for selectivity profiling. |
View IKZF1 Products |
| Related Target: IKZF2 | Helios (IKZF2) Protein & Lentivirus Paralog for counter-screening off-target transcription factor effects. |
View IKZF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Stability Assessment | Human CRBN and IKZF3 (WT & Q146H mutant) proteins available with >95% purity, Sequence Verified, ensuring reliable SPR/TR-FRET binding kinetics. |
| Homolog Counter Screening (IKZF1 vs IKZF3) | Homolog panel proteins (IKZF1, IKZF2, IKZF3) strictly verified by mass spec to validate true molecular glue selectivity. |
| Intracellular Degradation Validation | Lentiviral particles carrying sequence-perfect IKZF3 ORFs for rapid construction of stable degrader-reporter cell lines. |
| False Positives in Phenotypic Screens | Validated siRNA included for absolute target dependency checks. |
| Resistance Mechanism Profiling | Pre-made Q146H and Q147H mutants. Endotoxin-controlled for primary cell assays. |
Live Aiolos/IKZF3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Aiolos (IKZF3) therapeutics is dominated by targeted protein degradation. IKZF3 is an intracellular transcription factor critical to B-cell development and multiple myeloma survival, making it undruggable by conventional inhibitors. First-generation IMiDs (lenalidomide, pomalidomide) face resistance mutations in the zinc finger domain (e.g., Q146H). Next-generation molecular glues (CELMoDs) and PROTACs aim to form robust ternary complexes (CRBN–drug–IKZF3) even in refractory environments, while carefully mitigating off-target degradation of IKZF1 to improve safety profiles.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glues (CELMoDs) | BMS, Monte Rosa, Nurix, Biotheryx | Multiple Myeloma, Lymphomas, SLE | Ternary Complex SPR (Need high-purity IKZF3 WT & mutant, CRBN proteins) |
| PROTACs / Heterobifunctionals | Kymera, Arvinas, C4 Therapeutics | Refractory Blood Cancers, Lymphoma | Degradation Kinetics Assay (Need stable cell lines via Lentivirus ORF) |
| Small Molecule Inhibitors | Academic / Early Biotech | Autoimmune Diseases | Selectivity Assay (Need IKZF1/IKZF3 Homolog panels) |